World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibit ...
Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) ...
Human Endogenous Retroviruses linked to MS, Type 1 diabetes, ALS, schizophrenia GeNeuro’s temelimab most advanced drug candidate targeting pathogenic HERV Geneva, Switzerland, 11 July 2019 – 6:00pm CEST – GeNe ...
DATA SUPPORTS THERAPEUTIC ROLE OF GKT831 IN ADVANCED LIVER FIBROSIS Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis Genky ...
Research supports neurobiological rationale for evidence of neuroprotection obtained in completed Phase 2b clinical trials Protective effects on axonal degeneration and remyelination support potential role of teme ...
Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metric ...
